ライフサイエンスコーパス: small cell lung carcinoma

1 icroRNA (miR) expression is described in non-small cell lung carcinoma.

2 nduce DNA damage associated apoptosis in non-small cell lung carcinoma.

3 ssue confirmed RS/DJ-1 overexpression in non-small cell lung carcinoma.

4 diation therapy and chemotherapy for limited small cell lung carcinoma.

5 cyclins D1 and E is reported in invasive non-small cell lung carcinoma.

6 sistant NCI-H1688 cells derived from a human small cell lung carcinoma.

7 the skin which shares several features with small cell lung carcinoma.

8 n of treatment response in patients with non-small cell lung carcinoma.

9 s with non-metastatic surgically treated non-small-cell lung carcinoma.

10 ght to represent the preneoplastic lesion of small-cell lung carcinoma.

11 t has been investigated in patients with non-small-cell lung carcinoma.

12 angiogenesis) as a prognostic factor in non-small-cell lung carcinoma.

13 c carcinoma as well as in the H125 human non-small-cell lung carcinoma.

14 luding enteric/autonomic) usually related to small-cell lung carcinoma.

15 d in patients with refractory breast and non-small-cell lung carcinoma.

16 R index in 13 patients with grade 3 or 4 non-small-cell lung carcinoma.

17 bility of distinguishing small-cell from non-small-cell lung carcinoma.

18 t are overexpressed in prostate, breast, and small-cell lung carcinoma.

19 MAGE-A4 was expressed in 48% of non-small cell lung carcinomas.

20 3 mutation or both (P = 0.01) in primary non-small cell lung carcinomas.

21 ung carcinomas and to a lesser extent in non-small cell lung carcinomas.

22 ncy in human breast, colorectal, gastric and small cell lung carcinomas.

23 positive gliomas, breast carcinomas, and non-small cell lung carcinomas.

24 in the human bronchial epithelium and in non-small cell lung carcinomas.

25 ellular carcinomas, metastatic melanomas and small cell lung carcinomas.

26 stimulate growth of both small cell and non-small cell lung carcinomas.

27 ith the development of a subset of human non-small cell-lung carcinomas.

28 se expression is lost in >50% of primary non-small-cell lung carcinomas.

29 ripheral neurons, including synapses, and in small-cell lung carcinomas.

30 MDA-MB-468 breast, OV-1063 ovarian, and H-69 small-cell lung carcinomas.

31 ation in a series of 500 primary stage I non-small-cell lung carcinomas.

32 rodissected archival primary lung tumors (22 small cell lung carcinomas, 25 squamous cell carcinomas,

33 mRNA was detected in 8 of 11 neuroendocrine small cell lung carcinomas, 4 of 4 non-small cell lung c

34 ancreatic duct carcinoma (4 of 4 cases), non-small cell lung carcinoma (5 of 5 cases), soft tissue sa

35 d 1.3-fold for the moderately radiosensitive small cell lung carcinoma 54A and the highly radioresist

36 squamous cell carcinoma (FaDu), 19.9+/-1.9; small cell lung carcinoma (54A), 21.1+/-2.8; colon adeno

37 all cell lung cancer cell lines, 6 of 18 non-small cell lung carcinomas, 9 of 22 breast tumors, and 5

38 ) of breast carcinomas, 45% (5 of 11) of non-small cell lung carcinomas, 90% (9 of 10) of colon carci

39 Most small cell lung carcinomas (91%) and squamous cell carci

40 Among patients with small-cell lung carcinoma, African Americans have lower

41 e CC3 is a metastasis suppressor for variant small cell lung carcinoma and a mouse melanoma in vivo.

42 other major forms of lung cancers, including small cell lung carcinoma and adenocarcinomas.

43 here demonstrate that treatment of human non-small cell lung carcinoma and bladder carcinoma cells by

44 hich are widely used in the treatment of non-small cell lung carcinoma and other late-stage tumors.

45 RF in 53 human cell lines and 86 primary non-small cell lung carcinomas and correlated this with prev

46 (RASSF1A) was observed in 40% of primary non-small cell lung carcinomas and in several tumor cell lin

47 of RASSF1A was demonstrated in a majority of small cell lung carcinomas and to a lesser extent in non

48 oplasia was discovered in 68% (most commonly small-cell lung carcinoma and after collapsin response-m

49 he-art, mutant Kras-driven GEMMs--one of non-small-cell lung carcinoma and another of pancreatic aden

50 AIL sensitivity in pancreatic carcinoma, non-small-cell lung carcinoma and melanoma cell lines, and u

51 strated expression of amphiphysin in 8 of 10 small-cell lung carcinomas and in 5 of 14 breast carcino

52 oplasm, seven biopsied within 7 months (five small-cell lung carcinomas and two adenocarcinomas, one

53 MTDIA treatment inhibited A549 (human non-small cell lung carcinoma) and H358 (human bronchioloalv

54 ssues but has been described in gliomas, non-small cell lung carcinomas, and breast carcinomas, has p

55 3, which is lost in approximately 60% of non-small cell lung carcinomas, and exhibits growth-suppress

56 s, H-69 small cell lung carcinomas, H-23 non-small cell lung carcinomas, and MDA-MB-468 breast carcin

57 ic mesothelioma (n = 2), chemorefractory non-small-cell lung carcinoma, and bronchioloalveolar carcin

58 tient with platinum- and etoposide-resistant small-cell lung carcinoma, and minor responses were note

59 as been associated with neuronal tumours and small-cell lung carcinomas, and a frameshift mutant (RES

60 lymphomas, pancreatic cancer, glioblastoma, small-cell lung carcinomas, and in human nonmalignant pr

61 , expressed on the cell surface of human non-small cell lung carcinomas, are used here as a target fo

62 luding childhood acute myeloid leukemia; non-small cell lung carcinoma; arthrogryposis multiplex cong

63 ucted a genome-wide transcriptome map of non-small cell lung carcinomas based on gene-expression prof

64 growth factor receptor found on gliomas, non-small cell lung carcinomas, breast carcinomas, and ovari

65 mor cell lines, including human melanoma and small cell lung carcinoma, but not on normal primary lin

66 effective in vivo against NCI-H23 human non-small-cell lung carcinomas, but this modality was surpri

67 ere evaluated against the H69 parental human small cell lung carcinoma cell line and H69/LX4 resistan

68 uated against the COR-L23 parental human non small cell lung carcinoma cell line and the COR-L23/R re

69 ce were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with pac

70 )-induced COX-2 expression in H358 human non-small cell lung carcinoma cell line by blocking CDK2 act

71 boplatin cytotoxicity against the LX-1 human small cell lung carcinoma cell line in vitro.

72 n liver AKN-1 cell line and in the human non-small cell lung carcinoma cell line, A-549, the ability

73 In H-345 human small cell lung carcinoma cell line, conjugates of RC-12

74 However, 24-h exposure of a non-small cell lung carcinoma cell line, NCI H157, to 10 mic

75 deletion region of 5-7 Mb associated with a small cell lung carcinoma cell line, U2020, suggesting t

76 2, and a 3p14.2 homozygous deletion in a non-small cell lung carcinoma cell line.

77 cancer in 13 small cell carcinoma and 17 non-small cell lung carcinoma cell lines and in 68 microdiss

78 w that siRNA-mediated TRPC1 depletion in non small cell lung carcinoma cell lines induced G(0)/G(1) c

79 nd reduced levels of UNP protein in all four small cell lung carcinoma cell lines tested.

80 rrest and rapid apoptosis in three human non-small cell lung carcinoma cell lines with wild-type p53

81 When reintroduced into nonexpressing non-small cell lung carcinoma cell lines, this gene, named D

82 with the cytotoxicity of meayamycin B in non-small cell lung carcinoma cell lines.

83 evels of Bcl-2 and Bcl-XL proteins and a non-small-cell lung carcinoma cell line (NCI-H460).

84 calcium (Ca2+) channels were studied in the small-cell lung carcinoma cell line NCI-H345 using patch

85 y no direct role in the MDR phenotype in non-small cell lung carcinoma cells and that their cellular

86 by which EZH2 expression is regulated in non-small cell lung carcinoma cells by oncogenic KRAS.

87 t administration schedules in A549 human non-small cell lung carcinoma cells in vitro.

88 verexpression of the mda-7 gene in human non-small cell lung carcinoma cells in vivo and its effects

89 In concordance, cultured SCLC but not non-small cell lung carcinoma cells showed no or extremely l

90 noma) and H358 (human bronchioloalveolar non-small cell lung carcinoma cells) xenograft tumor growth

91 CaKi-1 renal cell carcinoma cells, human SW2 small cell lung carcinoma cells, human umbilical vein en

92 activation of JAK-STAT3 was also observed in small cell lung carcinoma cells, suggesting that this au

93 xenograft models based on human NCI-H460 non-small cell lung carcinoma cells.

94 and induced apoptosis in p53-null H1299 non-small cell lung carcinoma cells.

95 growth inhibition and apoptosis in human non-small cell lung carcinoma cells.

96 human p53 null Saos-2 osteosarcoma and H1299 small cell lung carcinoma cells.

97 nteraction between MTOR and ponatinib in non-small cell lung carcinoma cells.

98 V/PST and reduce NCAM polysialylation in SW2 small cell lung carcinoma cells.

99 minobutanoic acid (9) against A549 human non-small-cell lung carcinoma cells in culture were 23 and 2

100 ssion of GFI1 potentiates tumor formation of small-cell lung carcinoma cells.

101 calcium channel types that are expressed on small-cell lung carcinoma cells.

102 GRP antagonist inhibit the growth of DMS-153 small cell lung carcinoma concomitantly with the express

103 In patients with non-small cell lung carcinoma, differential display shows th

104 Human non-small cell lung carcinoma expressed varying levels of bo

105 ion at the FHIT locus in a series of 106 non-small cell lung carcinomas for which a full clinical, ep

106 rological disorders and in the regulation of small-cell lung carcinoma growth.

107 When U-87 glioblastomas, H-69 small cell lung carcinomas, H-23 non-small cell lung car

108 Here, using human non-small-cell lung carcinoma H1299 cells, we investigated t

109 overexpressed p300 and p73 in human p53-free small-cell lung carcinoma H1299 or osteosarcoma Saos-2 c

110 king down SSRP1 or Spt16 levels in human non-small cell lung carcinoma (H1299) cells.

111 Recent advances in therapy for non-small cell lung carcinoma have shown that a personalized

112 r suppression of pulmonary metastases of non-small cell lung carcinoma in both prophylactic and thera

113 litis developed as the presenting feature of small-cell lung carcinoma in 3 patients.

114 cancer-related mortality worldwide, with non-small-cell lung carcinomas in smokers being the predomin

115 Small-cell lung carcinoma is an aggressive form of lung

116 A 60-year-old man with a non-small cell lung carcinoma (large cell type) presented wi

117 n multiple tumor types, the RB-defective non-small cell lung carcinoma line H2009 and its RB-reconsti

118 sitivities persisted in an additional 22 non-small cell lung carcinoma lines (ras mutations, n = 12 a

119 .3 lymphoma, human CHL-1 melanoma, and SBC-3 small cell lung carcinoma lines from establishing tumors

120 Jurkat T lymphoma, CHL-1 melanoma, and SBC-3 small cell lung carcinoma lines.

121 ism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary pati

122 etected in 40% of the tumors, whereas in non-small cell lung carcinomas, lymphomas, and head and neck

123 ed in human hepatocellular carcinoma and non-small cell lung carcinoma, may facilitate cancer cell gr

124 malignant cell lines including leukemia, non-small cell lung carcinoma, melanoma, and breast cancer c

125 erexpressed on the surface of neuroblastoma, small-cell lung carcinoma, melanoma, and other human tum

126 Using a Kras-driven non-small cell lung carcinoma mouse model, we found that eit

127 This association was strongest for small-cell lung carcinomas (multivariate RR = 1.56, 95%

128 demonstrated that some other aggressive non-small-cell lung carcinomas (n-SCLC) do not have angiogen

129 F-7), colorectal adenocarcinoma (HT-29), non-small cell lung carcinoma (NCI-H460), and glioblastoma (

130 m of chromosome 3 is a common finding in non-small cell lung carcinoma (NSCLC) and is postulated to b

131 oth small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) and the second on chro

132 at VCP is significantly overexpressed in non-small cell lung carcinoma (NSCLC) as compared to normal

133 to identify chromosomal imbalances in 20 non-small cell lung carcinoma (NSCLC) biopsies and cell line

134 Microarray data from cell lines of Non-Small Cell Lung Carcinoma (NSCLC) can be used to look fo

135 tobacco-related lung disease, stimulates non-small cell lung carcinoma (NSCLC) cell growth and surviv

136 tin (Fn) stimulates the proliferation of non-small cell lung carcinoma (NSCLC) cell growth through th

137 essed EGFR at levels comparable with the non-small cell lung carcinoma (NSCLC) cell line A549, as sho

138 sin receptor subtype 3 [BRS-3]) in human non-small cell lung carcinoma (NSCLC) cell lines and bronchi

139 Because the majority of human non-small cell lung carcinoma (NSCLC) cell lines are resista

140 rative genomic and proteomic analysis of non-small cell lung carcinoma (NSCLC) cell lines revealed si

141 ase inhibitor PF2341066 in MET-amplified non-small cell lung carcinoma (NSCLC) cell lines to identify

142 s of DLC-1 protein expression identifies non-small cell lung carcinoma (NSCLC) cell lines whose growt

143 This method was applied to human non-small cell lung carcinoma (NSCLC) cell lines, embedded a

144 eviously showed that nicotine stimulates non-small cell lung carcinoma (NSCLC) cell proliferation thr

145 a matrix glycoprotein, stimulates human non-small cell lung carcinoma (NSCLC) cell proliferation.

146 ell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on

147 e a potent inducer of apoptosis in human non-small cell lung carcinoma (NSCLC) cells through a nuclea

148 ctase, the silencing of which sensitized non-small cell lung carcinoma (NSCLC) cells to the cytotoxic

149 as also essential for PML degradation in non-small cell lung carcinoma (NSCLC) cells, and PML and PIA

150 In studies performed in non-small cell lung carcinoma (NSCLC) cells, we found that P

151 various tumor cell lines including human non-small cell lung carcinoma (NSCLC) cells, which are resis

152 iscover the molecular targets of FHIT in non-small cell lung carcinoma (NSCLC) cells.

153 death worldwide, and among this cancer, non-small cell lung carcinoma (NSCLC) comprises the majority

154 ished that PKCvarepsilon is required for non-small cell lung carcinoma (NSCLC) growth in vitro as wel

155 Here, we demonstrate that HH-dependent non-small cell lung carcinoma (NSCLC) growth is sensitive to

156 is significance of TIL subpopulations in non-small cell lung carcinoma (NSCLC) have thus far not been

157 from static and parametric PET images of non-small cell lung carcinoma (NSCLC) in order to provide in

158 demonstrated that NE differentiation in non-small cell lung carcinoma (NSCLC) is not uncommon.

159 Non-small cell lung carcinoma (NSCLC) is promoted by the inc

160 Non-small cell lung carcinoma (NSCLC) is the leading cause o

161 ugh the Tumor-Node-Metastasis staging of non-small cell lung carcinoma (NSCLC) is the most effective

162 tumor suppressor is a frequent event in non-small cell lung carcinoma (NSCLC) leading to the activat

163 GF receptor (EGFR)-targeted therapies in non-small cell lung carcinoma (NSCLC) led to investigation o

164 GF receptor (EGFR) are effective in most non-small cell lung carcinoma (NSCLC) patients whose tumors

165 midine ((18)F-FLT) PET in advanced-stage non-small cell lung carcinoma (NSCLC) patients with an activ

166 e targeted to overcome the resistance of non-small cell lung carcinoma (NSCLC) to the AKT inhibitor M

167 RH) MZ-J-7-138 and JV-1-92 on H460 human non-small cell lung carcinoma (NSCLC) xenografted orthotopic

168 of action were investigated in NCI-H838 non-small cell lung carcinoma (NSCLC) xenografted s.c. into

169 ise to treat inoperable locally-advanced non-small cell lung carcinoma (NSCLC), a disease poorly cont

170 at chromosome 17q in the development of non-small cell lung carcinoma (NSCLC), and a number of known

171 -driving genes in patients with advanced non-small cell lung carcinoma (NSCLC), especially in those w

172 haracteristic of many cancers, including non-small cell lung carcinoma (NSCLC), head and neck squamou

173 ancreatic ductal adenocarinoma (PDAC) or non-small cell lung carcinoma (NSCLC), respectively, but des

174 erall survival in never smokers who have non-small cell lung carcinoma (NSCLC), we conducted a consis

175 letion involving region 8p21-22 in human non-small cell lung carcinoma (NSCLC), we examined alteratio

176 As JNK is frequently activated in non-small cell lung carcinoma (NSCLC), we investigated the r

177 study was to characterize the effects of non-small cell lung carcinoma (NSCLC)-associated mutations i

178 The presence of a non-small cell lung carcinoma (NSCLC)-related gene or genes

179 resistance in several cancers, including non-small cell lung carcinoma (NSCLC).

180 AIL) is capable of inducing apoptosis in non-small cell lung carcinoma (NSCLC).

181 ic disease to the brain in patients with non-small cell lung carcinoma (NSCLC).

182 d in the growth and progression of human non-small cell lung carcinoma (NSCLC).

183 metrics and histopathologic response in non-small cell lung carcinoma (NSCLC).

184 ygosity (LOH) on chromosome 3 at 3p21 in non-small cell lung carcinoma (NSCLC).

185 1q22-23 is observed at high frequency in non-small cell lung carcinoma (NSCLC).

186 oth small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC).

187 naplastic large-cell lymphoma (ALCL) and non-small cell lung carcinoma (NSCLC).

188 tissue pairs from Chinese patients with non-small cell lung carcinoma (NSCLC).

189 le ((18)F-FMISO) uptake in patients with non-small cell lung carcinoma (NSCLC).

190 t in epithelial cancers, particularly in non-small cell lung carcinoma (NSCLC).

191 elated with prognosis and progression of non-small cell lung carcinoma (NSCLC).

192 mal tissue samples from 17 patients with non-small cell lung carcinoma (NSCLC).

193 rapy in patients with radically resected non-small cell lung carcinoma (NSCLC).

194 sing new therapeutic agents for treating non-small cell lung carcinoma (NSCLC).

195 2 is highly expressed in the majority of non-small cell lung carcinomas (NSCLC) but not in normal lun

196 d in some lung tumors, the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had n

197 rotein is found in approximately 3-7% of non-small cell lung carcinomas (NSCLC).

198 s increased in lung cancer, particularly non-small cell lung carcinomas (NSCLC).

199 Non-small-cell lung carcinoma (NSCLC) accounts for 85% of ma

200 Our current study using non-small-cell lung carcinoma (NSCLC) cell lines, animal mod

201 its inhibitors and restores autophagy in non-small-cell lung carcinoma (NSCLC) cells with a TKI-sensi

202 s the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal g

203 As therapy for locally advanced non-small-cell lung carcinoma (NSCLC) improves, brain metast

204 Non-small-cell lung carcinoma (NSCLC) is among the deadliest

205 d the elevated level of EAPII protein in non-small-cell lung carcinoma (NSCLC) patients and NSCLC cel

206 tified that predict clinical response of non-small-cell lung carcinoma (NSCLC) patients to gefitinib.

207 of second- and third-line patients with non-small-cell lung carcinoma (NSCLC) with the epidermal gro

208 or (EGFR) is frequently overexpressed in non-small-cell lung carcinoma (NSCLC), and EGFR inhibitors a

209 in small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (NSCLC), the extent of such ab

210 more accurate than CT for the staging of non-small-cell lung carcinoma (NSCLC).

211 inical outcome in patients with resected non-small-cell lung carcinoma (NSCLC; n = 248).

212 unohistochemical analysis of a cohort of non-small-cell lung carcinomas (NSCLC) indicated that 15.5%

213 ; (4) normal versus colon tumor; and (5) Non-Small-Cell-Lung-Carcinoma (NSCLC) versus renal samples.

214 er 2013, solid tumour samples (including non-small-cell lung carcinoma [NSCLC], colorectal carcinoma,

215 MAP kinase pathway activation common in non-small cell lung carcinomas (NSCLCs) and to extend the in

216 (d-DT), have protumorigenic functions in non-small cell lung carcinomas (NSCLCs) but have AMPK-activa

217 ion and maintenance of Kras(G12V)-driven non-small cell lung carcinomas (NSCLCs).

218 observed in human cancers, but rarely in non-small cell lung carcinomas (NSCLCs).

219 Non-small-cell lung carcinomas (NSCLCs), which represent aro

220 lial adhesion and are often expressed in non-small-cell lung carcinomas (NSCLCs).

221 umor cell lines, and 98 resected primary non-small-cell lung carcinomas (NSCLCs).

222 cell carcinoma, the two major classes of non-small-cell lung carcinomas (NSCLCs).

223 titumor activity of Taxol in a MDR human non-small cell lung carcinoma nude mouse xenograft model.

224 Non-small-cell lung carcinomas of the superior sulcus, frequ

225 Non-small cell lung carcinoma patients are frequently treate

226 ncer cells isolated from peripheral blood of small cell lung carcinoma patients given chemotherapy.

227 d melanoma patients and three metastatic non-small cell lung carcinoma patients vaccinated with autol

228 naplastic lymphoma kinase (ALK)-positive non-small-cell lung carcinoma patients, progression during t

229 results in patients with ROS1-rearranged non-small-cell lung carcinoma, recently emerging clinical ev

230 o paraneoplastic visual disorders related to small-cell lung carcinoma: retinopathy ("CAR"-IgG [23kDa

231 , we observed that the majority (74%) of non-small cell lung carcinoma samples exhibited a significan

232 thways, and cell cycle abnormalities in both small cell lung carcinoma (SCLC) and in non-SCLC.

233 gment 9p23 in four samples representing both small cell lung carcinoma (SCLC) and non-small cell lung

234 etastatic disease are poorly defined in both small cell lung carcinoma (SCLC) and non-small cell lung

235 Although human small cell lung carcinoma (SCLC) cell lines are typicall

236 Here, we show that different human small cell lung carcinoma (SCLC) cell lines overexpress

237 e cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC) constitute a spectrum o

238 uman gene CC3 is a metastasis suppressor for small cell lung carcinoma (SCLC) in vivo.

239 Small cell lung carcinoma (SCLC) is a highly lethal, smo

240 roperties of a metastasis suppresor gene for small cell lung carcinoma (SCLC) is described.

241 Small cell lung carcinoma (SCLC) is extremely aggressive

242 nting a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 in

243 Small cell lung carcinoma (SCLC) often features the upre

244 expression of acetylcholine in normal lung, small cell lung carcinoma (SCLC) synthesize and secrete

245 es that are differentially over-expressed in Small Cell Lung Carcinoma (SCLC) we have used a combinat

246 n as an autocrine/paracrine growth factor in small cell lung carcinoma (SCLC).

247 factors responsible for the pathogenesis of small cell lung carcinoma (SCLC).

248 and differentially overexpressed in primary small cell lung carcinomas (SCLC).

249 ost frequent site for genetic alterations in small-cell lung carcinoma (SCLC) and non-small-cell lung

250 BT-737 triggers extensive cell death in many small-cell lung carcinoma (SCLC) cell lines, some of the

251 Small-cell lung carcinoma (SCLC) is a neuroendocrine sub

252 Small-cell lung carcinoma (SCLC) is an aggressive, rapid

253 In a human small-cell lung carcinoma (SCLC) primary xenograft model

254 rowth of neoplasms such as breast cancer and small-cell lung carcinoma (SCLC).

255 the mitogenesis of tumor cells such as human small-cell lung carcinoma (SCLC).

256 robable lung cancer (7 with biopsy-confirmed small cell lung carcinoma [SCLC]; 1 imaged only).

257 Cancer (majority small-cell lung carcinoma [SCLC]) was detected in 66 of

258 It is well established that small cell lung carcinomas (SCLCs) express receptors for

259 ygosity at 3p21.3 occurs in more than 90% of small cell lung carcinomas (SCLCs).

260 class I-restricted CTL to poorly immunogenic small cell lung carcinomas (SCLCs).

261 ubset of primary human cancers including non-small cell lung carcinoma, squamous cell skin carcinoma

262 Non-small cell lung carcinoma still maintains a poor 5-year

263 at PPP2R2A was commonly downregulated in non-small cell lung carcinomas, suggesting that PPP2R2A stat

264 014 to treat gastric adenocarcinomas and non-small cell lung carcinomas, targets vascular endothelial

265 Strikingly, patients with non-small cell lung carcinoma that had received WGP treatmen

266 Finally, we found that non-small-cell lung carcinoma that presented a cytonuclear Z

267 combined-modality therapy for stage IIIA non-small cell lung carcinoma, the signs and symptoms of pol

268 sion of Hu antigens is most commonly seen in small-cell lung carcinoma, their exact identity (e.g., H

269 Using non-small cell lung carcinoma to illustrate this approach, w

270 in a panel of established small cell and non-small cell lung carcinoma tumor cell lines.

271 50%) of DAL-1 was measured in 39 primary non-small cell lung carcinoma tumors as compared with patien

272 18p11.3, which is lost in 38% of primary non-small cell lung carcinoma tumors.

273 esponse to chemotherapy in patients with non-small cell lung carcinoma using functional diffusion map

274 rate that Hel-NI and Hel-N2 are expressed in small-cell lung carcinoma using reverse transcription-po

275 phase II trial of patients with advanced non-small-cell lung carcinoma using the 72-h infusion every

276 ssor that inhibits metastasis of the variant small cell lung carcinoma (v-SCLC) by predisposing cells

277 Small cell lung carcinoma was diagnosed in the patient w

278 ntly in clinical trials for the treatment of small cell lung carcinoma, was synthesized using this st

279 Twenty-one of the twenty-four non-small-cell-lung carcinomas we analyzed express IWS1.

280 One hundred consecutive patients with non-small cell lung carcinoma were referred for CT evaluatio

281 crine small cell lung carcinomas, 4 of 4 non-small cell lung carcinomas with neuroendocrine phenotype

282 Axl monoclonal antibodies that attenuate non-small cell lung carcinoma xenograft growth by downregula

283 /GRP) antagonist RC-3940-II on DMS-153 human small cell lung carcinoma xenografted into nude mice.

284 pendent human PANC-1 pancreatic and A549 non-small-cell lung carcinoma xenografts in nude mice, effec